QI
CCXI

QS Investors’s ChemoCentryx, Inc. CCXI Stock Holding History

QS Investors’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-643
Closed -$9K – 1694
2019
Q1 		$9K Hold
643
– – ﹤0.01% 1557
2018
Q4 		$8K Hold
643
– – ﹤0.01% 1534
2018
Q3 		$8K Hold
643
– – ﹤0.01% 1570
2018
Q2 		$8K Buy
+643
New +$7.69K ﹤0.01% 1586

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QS Investors's CCXI Position: Q2 2019 in Review

QS Investors sold out of ChemoCentryx, Inc. (CCXI) in Q2 2019, closing a stake of 643 shares — an estimated $9K sold.

QS Investors first reported a position in CCXI in Q2 2018 and held it in 4 quarters. The position peaked at $9K in Q1 2019. 117 funds tracked by Wall St. Rank hold CCXI as of Q2 2019.

  • QS Investors reported no remaining ChemoCentryx, Inc. position as of Q2 2019 after selling out during the quarter.
  • QS Investors sold 643 ChemoCentryx, Inc. shares in Q2 2019, an estimated $9K.
  • QS Investors first reported a position in ChemoCentryx, Inc. in Q2 2018 and held it in 4 quarters.
  • QS Investors's ChemoCentryx, Inc. position peaked at $9K in Q1 2019.
  • 117 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2019.

Based on QS Investors's 13F filing for Q2 2019, filed 14 Aug 2019.